Positive Outcomes from the RIVER Trial of Haduvio
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, recently shared positive topline results from its Phase 2a trial known as the RIVER trial. This trial assessed the effectiveness of Haduvio, an investigational therapy designed to treat refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF) patients. The results demonstrated that Haduvio achieved a statistically significant reduction in 24-hour cough frequency, with a notable 57% placebo-adjusted change from baseline.
Haduvio's Impact on Cough Frequency
The primary endpoint of demonstrating a reduction in objective 24-hour cough frequency was successfully met, showcasing a substantial reduction of 67% from baseline among patients receiving the 108 mg BID dose. Comparable efficacy was observed across patients with both moderate and severe cough, affirming the robustness of Haduvio's effectiveness.
Secondary Outcomes and Patient Feedback
In addition to the primary endpoint results, patients reported various secondary outcomes that were statistically significant. Positive feedback from patients regarding symptom relief was consistent with the primary findings, underscoring Haduvio's potential to alleviate symptoms associated with chronic cough.
Jennifer Good, the President and CEO of Trevi Therapeutics, expressed her excitement about the trial outcomes, stating, "These results mark a significant milestone in our efforts to address a condition that has no approved therapies available in the U.S. We are encouraged by the results indicating Haduvio's efficacy at low doses, which could lead to improved treatment options for patients suffering from chronic cough."
Expert Opinions on Haduvio
Professor Jacky Smith, an authority in respiratory medicine, noted the critical nature of these findings. She emphasized that RCC can lead to serious physical and psychological challenges for patients, calling for more effective therapies to manage this debilitating condition. The RIVER trial results showcased how Haduvio could play a pivotal role in addressing these patient needs.
Trial Structure and Methodology
The Phase 2a RIVER trial was meticulously structured as a randomized, double-blind, placebo-controlled study, involving 66 patients diagnosed with RCC. Each participant underwent two treatment periods lasting 21 days, with assessments conducted after titrating the therapy to several dosage levels. This robust methodology aimed to ensure that findings were both reliable and applicable.
This extensive data collection included patients receiving various doses of Haduvio, allowing the team to closely monitor cough frequency and other relevant health metrics throughout the trial. Following this enriched analytical process, the feedback and data collected will now guide the next steps in the therapy’s development.
Safety and Tolerability of Haduvio
The trial also evaluated safety outcomes, which consistently aligned with known profiles from earlier studies. While participants did experience common side effects such as constipation and headache, there were no serious adverse events reported, reinforcing the drug's safety for consideration in future treatments.
Next Steps for Trevi Therapeutics
With these promising results, Trevi Therapeutics plans to engage with regulatory authorities to discuss potential pathways to advance Haduvio's development further. The company aims to propose an additional study based on feedback from regulatory insights. They remain committed to meeting the needs of patients suffering from these chronic conditions.
About Refractory Chronic Cough (RCC)
RCC is characterized by a cough lasting over eight weeks despite ongoing treatments for underlying conditions. It affects millions of patients and can lead to significant lifestyle disruptions. The condition is marked by hyperreactivity of the cough reflex within the central and peripheral nervous systems, causing a wide array of complications, including anxiety and social embarrassment.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is dedicated to developing innovative therapies aimed at addressing unmet medical needs. By focusing on persistent cough conditions like RCC and IPF, the company strives to provide effective and safe treatment solutions. They are enthusiastic about Haduvio's potential to help improve the lives of those affected by chronic cough.
Frequently Asked Questions
What are the primary results of the Phase 2a RIVER trial?
The trial showed a statistically significant reduction in 24-hour cough frequency, with a 67% decrease from baseline and a 57% placebo-adjusted change.
What was the sample size for the RIVER trial?
There were 66 participants involved in the Phase 2a RIVER trial, helping to assess the efficacy of Haduvio on chronic cough.
How safe is Haduvio according to the trial results?
The safety profile of Haduvio was consistent with previous studies, with only mild adverse effects reported and no serious adverse events.
What future plans does Trevi Therapeutics have for Haduvio?
Trevi plans to engage with regulatory bodies to discuss further development pathways and is aiming to initiate the next study after receiving input.
Why is RCC considered a challenging condition to treat?
RCC has no approved therapies available in the U.S., leading to significant patient suffering and urgency for effective treatments.
